(Q34163110)

31 July 2017

1 reference

title

Effects of current therapeutic interventions on insulin resistance (English)

1 reference

31 July 2017

1 reference

1 reference

Kobayashi M

1

1 reference

31 July 2017

publication date

1 May 1999

1 reference

Diabetes, Obesity and Metabolism

31 July 2017

published in

1 reference

31 July 2017

volume

1 Suppl 1

1 reference

31 July 2017

page(s)

S32-40

1 reference

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

New treatments for patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Metformin: a new oral biguanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Antihyperglycaemic agents. Drug interactions of clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

21 January 2018

Insulin use in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

The pharmacology of sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Treatment of NIDDM with insulin agonists or substitutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

Daily walking combined with diet therapy is a useful means for obese NIDDM patients not only to reduce body weight but also to improve insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.0010S1032.X

10.1046/J.1463-1326.1999.0010S1032.X

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bwftw2dpwrbprprem6umpz7acy

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_bwftw2dpwrbprprem6umpz7acy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bwftw2dpwrbprprem6umpz7acy

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/bwftw2dpwrbprprem6umpz7acy

1 reference